Quarterly ResultMay 7, 2026, 04:38 PM
NextCure Q1 Net Loss $9.8M; Going Concern Warning Issued
AI Summary
NextCure, Inc. reported a net loss of $9.8 million for the first quarter of 2026, an improvement from $11.0 million in the prior year. The company issued a going concern warning, stating that its $29.7 million in cash, cash equivalents, and marketable securities as of March 31, 2026, will not be sufficient to fund operations for one year. NextCure continues to focus on advancing its clinical-stage biopharmaceutical programs while implementing cost-reduction measures and seeking additional funding.
Key Highlights
- Issued a going concern warning, indicating insufficient funds for one year of operations.
- Reported Q1 2026 net loss of $9.8 million, an improvement from $11.0 million in Q1 2025.
- Net loss per common share was $(1.87) in Q1 2026, compared to $(4.70) in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $29.7 million as of March 31, 2026.
- Research and development expenses decreased to $6.8 million from $7.9 million year-over-year.
- General and administrative expenses decreased to $3.3 million from $3.7 million year-over-year.
- Net cash used in operating activities was $13.4 million for the three months ended March 31, 2026.
- Sold 99,446 common shares for $1.2 million net proceeds via an at-the-market offering.